Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase

Journal of Medicinal Chemistry

Volumn 58, Issue 14, 2015, Pages 5437-5444

  Smith, Christopher R ^a   Dougan, Douglas R ^a   Komandla, Mallareddy ^a   Kanouni, Toufike ^a   Knight, Beverly ^a   Lawson, J David ^a   Sabat, Mark ^a   Taylor, Ewan R ^a   Vu, Phong ^a   Wyrick, Corey ^a  

^a Takeda San Diego Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 8 (5 METHYL 1H INDAZOL 6 YL)CINNOLINE 3 CARBOXAMIDE; 4 AMINOCINNOLINE 3 CARBOXAMIDE DERIVATIVE; ADENOSINE TRIPHOSPHATE; ANTIRHEUMATIC AGENT; BRUTON TYROSINE KINASE; BRUTON TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; AGAMMAGLOBULINAEMIA TYROSINE KINASE; COLLAGEN; LIGAND; MOLECULAR LIBRARY; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTHRITIS; ARTICLE; BINDING AFFINITY; BINDING SITE; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; MOLECULAR DOCKING; MOUSE; NONHUMAN; PAW EDEMA; RAT; X RAY CRYSTALLOGRAPHY; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMICALLY INDUCED; CHEMISTRY; DOG; DRUG DEVELOPMENT; FEMALE; MALE; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; PROTEIN CONFORMATION; THERAPEUTIC USE;

ADENOSINE TRIPHOSPHATE; ANIMALS; ARTHRITIS; BINDING SITES; COLLAGEN; DOGS; DRUG DISCOVERY; FEMALE; LIGANDS; MALE; MICE; MODELS, MOLECULAR; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RATS; SMALL MOLECULE LIBRARIES;

EID: 84937714456     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00734     Document Type: Article

References (29)

1. Firestein, G. S. Evolving concepts of rheumatoid arthritis Nature 2003, 423 (6937) 356-361
2. Kremer, J. M.; Bloom, B. J.; Breedveld, F. C.; Coombs, J. H.; Fletcher, M. P.; Gruben, D.; Krishnaswami, S.; Burgos-Vargas, R.; Wilkinson, B.; Zerbini, C. A.; Zwillich, S. H. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo Arthritis Rheum. 2009, 60 (7) 1895-1905
3. Flanagan, M. E.; Blumenkopf, T. A.; Brissette, W. H.; Brown, M. F.; Casavant, J. M.; Shang-Poa, C.; Doty, J. L.; Elliott, E. A.; Fisher, M. B.; Hines, M.; Kent, C.; Kudlacz, E. M.; Lillie, B. M.; Magnuson, K. S.; McCurdy, S. P.; Munchhof, M. J.; Perry, B. D.; Sawyer, P. S.; Strelevitz, T. J.; Subramanyam, C.; Sun, J.; Whipple, D. A.; Changelian, P. S. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection J. Med. Chem. 2010, 53 (24) 8468-8484
4. Tsukada, S.; Saffran, D. C.; Rawlings, D. J.; Parolini, O.; Allen, R. C.; Klisak, I.; Sparkes, R. S.; Kubagawa, H.; Mohandas, T.; Quan, S.; Belmont, J. W.; Cooper, M. D.; Conley, M. E.; Witte, O. N. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia Cell 1993, 72 (2) 279-290
5. Kawakami, Y.; Yao, L.; Miura, T.; Tsukada, S.; Witte, O. N.; Kawakami, T. Tyrosine phosphorylation and activation of Bruton tyrosine kinase upon Fc epsilon RI cross-linking Mol. Cell. Biol. 1994, 14 (8) 5108-5113
6. Smith, C. I.; Baskin, B.; Humire-Greiff, P.; Zhou, J. N.; Olsson, P. G.; Maniar, H. S.; Kjellen, P.; Lambris, J. D.; Christensson, B.; Hammarstrom, L. Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells J. Immunol. 1994, 152 (2) 557-565
7. de Weers, M.; Verschuren, M. C.; Kraakman, M. E.; Mensink, R. G.; Schuurman, R. K.; van Dongen, J. J.; Hendriks, R. W. The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages Eur. J. Immunol. 1993, 23 (12) 3109-3114
8. Lachance, G.; Levasseur, S.; Naccache, P. H. Chemotactic factor-induced recruitment and activation of Tec family kinases in human neutrophils. Implication of phosphatidynositol 3-kinases J. Biol. Chem. 2002, 277 (24) 21537-21541
9. Gagliardi, M. C.; Finocchi, A.; Orlandi, P.; Cursi, L.; Cancrini, C.; Moschese, V.; Miyawaki, T.; Rossi, P. Bruton's tyrosine kinase defect in dendritic cells from X-linked agammaglobulinaemia patients does not influence their differentiation, maturation and antigen-presenting cell function Clin. Exp. Immunol. 2003, 133 (1) 115-122
10. Whyatt, D.; Lindeboom, F.; Karis, A.; Ferreira, R.; Milot, E.; Hendriks, R.; de Bruijn, M.; Langeveld, A.; Gribnau, J.; Grosveld, F.; Philipsen, S. An intrinsic but cell-nonautonomous defect in GATA-1-overexpressing mouse erythroid cells Nature 2000, 406 (6795) 519-524
11. Robinson, D.; Chen, H. C.; Li, D.; Yustein, J. T.; He, F.; Lin, W. C.; Hayman, M. J.; Kung, H. J. Tyrosine kinase expression profiles of chicken erythro-progenitor cells and oncogene-transformed erythroblasts J. Biomed. Sci. 1998, 5 (2) 93-100
12. Quek, L. S.; Bolen, J.; Watson, S. P. A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen Curr. Biol. 1998, 8 (20) 1137-1140
13. Phillips, R. L.; Ernst, R. E.; Brunk, B.; Ivanova, N.; Mahan, M. A.; Deanehan, J. K.; Moore, K. A.; Overton, G. C.; Lemischka, I. R. The genetic program of hematopoietic stem cells Science 2000, 288 (5471) 1635-1640
14. Brunner, C.; Muller, B.; Wirth, T. Bruton's Tyrosine Kinase is involved in innate and adaptive immunity Histol. Histopathol. 2005, 20 (3) 945-955
15. Di Paolo, J. A.; Huang, T.; Balazs, M.; Barbosa, J.; Barck, K. H.; Bravo, B. J.; Carano, R. A.; Darrow, J.; Davies, D. R.; DeForge, L. E.; Diehl, L.; Ferrando, R.; Gallion, S. L.; Giannetti, A. M.; Gribling, P.; Hurez, V.; Hymowitz, S. G.; Jones, R.; Kropf, J. E.; Lee, W. P.; Maciejewski, P. M.; Mitchell, S. A.; Rong, H.; Staker, B. L.; Whitney, J. A.; Yeh, S.; Young, W. B.; Yu, C.; Zhang, J.; Reif, K.; Currie, K. S. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis Nature Chem. Biol. 2011, 7 (1) 41-50
16. Lou, Y.; Han, X.; Kuglstatter, A.; Kondru, R. K.; Sweeney, Z. K.; Soth, M.; McIntosh, J.; Litman, R.; Suh, J.; Kocer, B.; Davis, D.; Park, J.; Frauchiger, S.; Dewdney, N.; Zecic, H.; Taygerly, J. P.; Sarma, K.; Hong, J.; Hill, R. J.; Gabriel, T.; Goldstein, D. M.; Owens, T. D. Structure-Based Drug Design of RN486, a Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis J. Med. Chem. 2015, 58 (1) 512-516
17. Xu, D.; Kim, Y.; Postelnek, J.; Vu, M. D.; Hu, D. Q.; Liao, C.; Bradshaw, M.; Hsu, J.; Zhang, J.; Pashine, A.; Srinivasan, D.; Woods, J.; Levin, A.; O'Mahony, A.; Owens, T. D.; Lou, Y.; Hill, R. J.; Narula, S.; DeMartino, J.; Fine, J. S. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents J. Pharmacol. Exp. Ther. 2012, 341 (1) 90-103
18. Liu, L.; Di Paolo, J.; Barbosa, J.; Rong, H.; Reif, K.; Wong, H. Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy J. Pharmacol. Exp. Ther. 2011, 338 (1) 154-163
19. Kim, K. H.; Maderna, A.; Schnute, M. E.; Hegen, M.; Mohan, S.; Miyashiro, J.; Lin, L.; Li, E.; Keegan, S.; Lussier, J.; Wrocklage, C.; Nickerson-Nutter, C. L.; Wittwer, A. J.; Soutter, H.; Caspers, N.; Han, S.; Kurumbail, R.; Dunussi-Joannopoulos, K.; Douhan, J., III; Wissner, A. Imidazo[1,5- a ]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis Bioorg. Med. Chem. Lett. 2011, 21 (21) 6258-6263
20. Chang, B. Y.; Huang, M. M.; Francesco, M.; Chen, J.; Sokolove, J.; Magadala, P.; Robinson, W. H.; Buggy, J. J. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells Arthritis Res. Ther. 2011, 13 (4) R115
21. Honigberg, L. A.; Smith, A. M.; Sirisawad, M.; Verner, E.; Loury, D.; Chang, B.; Li, S.; Pan, Z.; Thamm, D. H.; Miller, R. A.; Buggy, J. J. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Proc. Natl. Acad. Sci. U. S. A. 2010, 107 (29) 13075-13080
22. Shi, Q.; Tebben, A.; Dyckman, A. J.; Li, H.; Liu, C.; Lin, J.; Spergel, S.; Burke, J. R.; McIntyre, K. W.; Olini, G. C.; Strnad, J.; Surti, N.; Muckelbauer, J. K.; Chang, C.; An, Y.; Cheng, L.; Ruan, Q.; Leftheris, K.; Carter, P. H.; Tino, J.; De Lucca, G. V. Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases Bioorg. Med. Chem. Lett. 2014, 24 (9) 2206-2211
23. Straus, D. B.; Weiss, A. Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor Cell 1992, 70 (4) 585-593
24. Pan, Z.; Scheerens, H.; Li, S. J.; Schultz, B. E.; Sprengeler, P. A.; Burrill, L. C.; Mendonca, R. V.; Sweeney, M. D.; Scott, K. C.; Grothaus, P. G.; Jeffery, D. A.; Spoerke, J. M.; Honigberg, L. A.; Young, P. R.; Dalrymple, S. A.; Palmer, J. T. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase ChemMedChem 2007, 2 (1) 58-61
25. Hann, M. M.; Keseru, G. M. Finding the sweet spot: the role of nature and nurture in medicinal chemistry Nature Rev. Drug Discovery 2012, 11 (5) 355-365
26. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9 (10) 430-431
27. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nature Rev. Drug Discovery 2007, 6 (11) 881-890
28. Dubenko, R. G. Arylhydrazones of substituted glyoxalic acids. IV Zh. Org. Khim. 1965, 1 (7) 1255-1260
29. Miyaura, N.; Ishiyama, T.; Sasaki, H.; Ishikawa, M.; Sato, M.; Suzuki, A. Palladium- catalyzed inter- and intramolecular cross- coupling reactions of B-alkyl-9-borabicyclo[3.3.1] nonane derivatives with 1-halo-1-alkenes or haloarenes. Syntheses of functionalized alkenes, arenes, and cycloalkenes via a hydroboration- coupling sequence J. Am. Chem. Soc. 1989, 111 (1) 314-321